PTPN22

Across TCGA pan-cancer cohorts, PTPN22 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of PTPN22’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PTPN22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PTPN22 is over-expressed in tumor, although a few such as LUSC and COAD show the opposite, repressed pattern.

KIRC, KIRP, and LUSC are the cancer types where PTPN22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTPN22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+1.478	<.001	11	view →
KIRP	Male	All	+0.698	<.001	9	view →
LUSC	All	II,III,IV	−1.382	<.001	8	view →
HNSC	All	All	+0.412	.005	6	view →
STAD	Female	All	+1.434	.003	4	view →
COAD	Female	All	−0.695	<.001	4	view →
BRCA	Female	All	+0.375	.001	4	view →
THCA	All	IV	+0.869	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

PTPN22–KIRC

Open the KIRC breakdown →